Shares of Eli Lilly (LLY) are jumping in early trading. The drugmaker reported second quarter results that handily beat Street estimates. The company also raised its full-year earnings and revenue guidance. Elil Lilly benefited from strong sales of its GLP-1 drugs Mounjaro and Zepbound.

Yahoo Finance healthcare reporter Anjalee Khemlani breaks down the results in the video above.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Stephanie Mikulich.